This protocol is provided for use with the FDA-cleared range of CytoCell® FISH probe kits for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Reference the Package Insert (Instructions for Use (IFU)) for warnings, precautions, storage, and handling. Study the Package Insert carefully before using this quick reference guide.
Note: This quick reference guide does not replace the content from the Package Insert.
The FISH probes are provided in a 100μl (10 test) per vial, ready-to-use format and premixed with hybridization solution (formamide; dextran sulfate; saline-sodium citrate (SSC)). In addition a 150μl vial of ready-to-use DAPI counterstain with antifade (0.125μg/ml DAPI (4,6-diamidino-2-phenylindole)) is provided. See Package Insert for additional details.
The CytoCell AML/MDS range of FISH probe test kits are used to detect common chromosomal rearrangements in fixed bone marrow specimens from patients with AML or MDS. The tests are indicated for the characterization of patient specimens consistent with World Health Organization guidelines for Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition) and in conjunction with other clinicopathological criteria. The assay results are to be interpreted by a qualified pathologist or cytogeneticist. The tests are not intended for use as a stand-alone diagnostic, disease screening, or as a companion diagnostic.
Refer to individual test kit Package Insert for the specific intended use and limitations.
For In Vitro Diagnostic Use. Rx only.